NASDAQ
26.01.26 | 22:00
22,460 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Goldman Sachs nimmt Bewertung für Arcus Biosciences mit "Buy" wieder auf | 1 | Investing.com Deutsch | ||
| 12.01. | Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating | 1 | Investing.com | ||
| 08.01. | Morgan Stanley downgrades Arcus Biosciences stock on balanced risk/reward | 1 | Investing.com | ||
| 18.12.25 | Arcus Biosciences passt Kreditfazilität an und verlängert Laufzeit | 2 | Investing.com Deutsch | ||
| 15.12.25 | RCUS Stock Down on Decision to Discontinue GILD Partnered Study | 3 | Zacks | ||
| 12.12.25 | Arcus Biosciences Shares Drop 12% After Discontinuing Phase 3 STAR-221 Trial | - | RTTNews | ||
| 12.12.25 | H.C. Wainwright raises Arcus Biosciences stock price target to $32 on lower expenses | 1 | Investing.com | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 12.12.25 | Truist Securities lowers Arcus Biosciences stock price target on trial failure | 1 | Investing.com | ||
| 12.12.25 | Arcus Biosciences: H.C. Wainwright hebt Kursziel wegen geringerer Kosten auf 32 US-Dollar an | 2 | Investing.com Deutsch | ||
| 12.12.25 | Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak | 1 | Investor's Business Daily | ||
| 12.12.25 | Arcus Biosciences And Gilead Discontinue Phase 3 STAR-221 Study In Cancer Due To Futility | 549 | AFX News | FOSTER CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Friday the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead... ► Artikel lesen | |
| 12.12.25 | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.10.25 | Arcus Biosciences stock falls after pricing $250 million public offering | 3 | Investing.com | ||
| 31.10.25 | Arcus Biosciences prices $250M offering | 2 | Seeking Alpha | ||
| 31.10.25 | Arcus Biosciences prices $250 million public offering at $18.25 per share | 2 | Investing.com | ||
| 30.10.25 | Hedge Fund and Insider Trading News: Paul Tudor Jones, Berkshire Hathaway, Soros Fund Management, Citadel Investment Group, LMR Partners, Iridium Communications Inc (IRDM), Arcus Biosciences Inc (RCUS), and More | 11 | Insider Monkey | ||
| 30.10.25 | Arcus Biosciences launches public offering of common stock | 1 | Investing.com | ||
| 29.10.25 | Analyst Expectations For Arcus Biosciences' Future | 2 | Benzinga.com | ||
| 28.10.25 | Arcus Biosciences: EPS übertrifft Schätzungen um 0,01 $ - Umsatz besser als erwartet | 2 | Investing.com Deutsch | ||
| 28.10.25 | Arcus Biosciences GAAP EPS of -$1.27 beats by $0.06, revenue of $26M beats by $5.75M | 1 | Seeking Alpha |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,63 | +0,04 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 294,04 | 0,00 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| QIAGEN | 46,430 | 0,00 % | AKTIE IM FOKUS: Qiagen testen Dreijahreshoch - Übernahmefantasie als Treiber | FRANKFURT (dpa-AFX) - Nach einem Sprung auf den höchsten Stand seit Februar 2023 hat die Aktie von Qiagen am Donnerstag ihre Gewinne fast vollständig abgegeben. Zuletzt ging es nur noch um 0,5 Prozent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,860 | +3,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,220 | -0,57 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,560 | +0,42 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,960 | +1,37 % | ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? | ||
| NUVALENT | 106,01 | 0,00 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,590 | 0,00 % | Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns | ||
| ARCELLX | 68,55 | +1,26 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ERASCA | 9,605 | -3,56 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,000 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE... ► Artikel lesen | |
| CG ONCOLOGY | 53,30 | -0,95 % | What Analysts Are Saying About CG Oncology Stock | ||
| KINIKSA PHARMACEUTICALS | 43,200 | +2,37 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,02 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen |
ARCUS BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 22,460 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.